FDA Grants Zanubrutinib Breakthrough Designation for Mantle Cell Lymphoma

January 15, 2019 – The FDA has granted the investigational BTK inhibitor zanubrutinib (BGB-3111) a breakthrough therapy designation for the treatment of adult patients with mantle cell lymphoma (MCL) who have previously received at least 1 prior therapy, according to BeiGene, the company manufacturing the agent. “We are very excited to receive the breakthrough therapy designation from the FDA,” said Jane Huang, MD, chief medical officer, Hematology, of BeiGene, in … (leggi tutto)